UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported):
October 31, 2014
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
001-34566 |
75-2308816 |
(State or other jurisdiction of |
(Commission File No.) |
(IRS Employer ID No.) |
incorporation or organization) |
|
|
18th Floor, Jialong International Building |
19 Chaoyang Park Road |
Chaoyang District, Beijing 100125 |
People’s Republic of China |
(Address of Principal Executive Offices)
86-10-6698-3166
Registrant's telephone number, including
area code
____________________________________________________________
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item
8.01 Other Events.
On November 3, 2014, China Biologic Products,
Inc. (the “Company”) issued a press release announcing that its majority-owned subsidiary, Shandong Taibang Biological
Products Co. Ltd., received on October 31, 2014 the approval from the Hebei Provincial Health and Family Planning Commission to
build two new plasma collection stations in Hebei Province, China. A copy of the press release is attached as Exhibit 99.1 to this
current report and is incorporated herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit Number |
Description |
|
|
99.1 |
Press release issued by the Company dated November 3, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 3, 2014 |
CHINA BIOLOGIC
PRODUCTS, INC. |
|
|
|
By: |
/s/ David (Xiaoying) Gao |
|
|
David (Xiaoying) Gao Chief Executive Officer |
Exhibit 99.1
![](image_001.jpg)
FOR RELEASE November 3, 2014
China Biologic to Build Two New Plasma
Collection Stations in Hebei Province
BEIJING, China – November 3, 2014
– China Biologic Products, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading
fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary Shandong Taibang
Biological Products Co. Ltd. (“Shandong Taibang”) received on October 31, 2014 the approval from the Hebei Provincial
Health and Family Planning Commission to build two new plasma collection stations in Hebei Province.
The new plasma collection stations will
be located in Xinglong County of Chengde City and Daming County of Handan City. These two counties have a combined population of
approximately one million. The Company intends to acquire the requisite land use rights and obtain the construction permits as
soon as it completes the site selection process, and will try to complete construction, staff recruitment and government inspection
and certification process within approximately 12 months thereafter. The aggregate capital expenditures for these two new collection
stations are expected to be in the range of RMB40 million to RMB50 million, or approximately $6.5 million to $8.1 million based
on the current exchange rate. Each new collection station may commence operations only after it passes a government inspection
and certification process and obtains a collection license. The Company expects these two new stations to reach their designed
annual collection capacities in approximately three years after obtaining collection licenses, by which time these two new stations
are expected to increase the Company’s total collection capacity by approximately 10-15%.
Mr. David (Xiaoying) Gao, Chairman
and Chief Executive Officer of China Biologic, commented, “We are very pleased to announce the approval to build two
new collection stations in Hebei Province, where the Company has significant market presence. Hebei, with a combined
population of approximately 71 million, is an underdeveloped province for plasma collection as there are currently three
stations only. The approval obtained by China Biologic is the first issued by the Hebei provincial government since plasma
collection was privatized in China in 2006.”
“The region is geographically advantageous
for us because it is close to Shandong and offers convenient and economic transportation for raw materials to our Shandong Taibang
manufacturing facility. Additionally, Hebei has a relatively low occurrence of infectious disease and therefore offers a good pool
of eligible plasma donors. The establishment of these two new collection stations in Hebei will represent a significant step for
carrying out China Biologic’s strategic business development plan. With the continuing expansion of our plasma collection
capacity and advancement of our product pipeline, we believe we are well positioned to meet the increasing market demands for plasma
protein therapeutics in China in the coming years,” Mr. Gao concluded.
About China Biologic Products, Inc.
China Biologic is a leading plasma-based
biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the
prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in
Beijing and manufactures over 20 different dosages of plasma-based products through its indirect majority-owned subsidiaries, Shandong
Taibang Biological Products Co., Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment
in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and inoculation centers, as well as distributors,
in China. For additional information, please see the Company's website, www.chinabiologic.com.
Safe Harbor Statement
This news release may contain certain “forward-looking
statements” relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements
of historical fact included herein, are “forward-looking statements.” These forward-looking statements are often identified
by the use of forward-looking terminology such as “intend,” “believe,” “expect,” “are
expected to,” “will,” or similar expressions, and involve known and unknown risks and uncertainties. Among other
things, the Company’s plan regarding the construction of the collection stations, the time required for the collection stations
to reach their designed capacities and quotations from management in this news release contain forward-looking statements. Although
the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions,
risks, and uncertainties, and these expectations may prove to be incorrect.
Investors should not place undue reliance
on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could
differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including, without
limitation potential delay or failure in acquiring land use rights, obtaining construction permits, completing the design or construction,
or passing the government inspection and certification process for the new collection stations in Hebei province, potential inability
to achieve the designed collection capacities at the new collection stations, potential inability to achieve the expected operating
and financial performance, potential inability to find alternative sources of plasma, potential inability to increase production
at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through
cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks
and uncertainties discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission
and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting
on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the
Company does not assume a duty to update these forward-looking statements.
Contact:
China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com
ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: bill.zima@icrinc.com
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024